leadf
logo-loader
viewVenus Metals Corporation Ltd
(
ASX:VMC
)

Venus Metals agrees to settle proceedings following court-supervised mediation

DJ Carmichael (on behalf of DJ Carmichael, Paul Adams and David Bosio) will the pay $150,000 to Venus as a contribution to Venus’ legal costs.

Venus Metals Corporation Ltd - Venus Metals agrees to settle proceedings following court-supervised mediation
The case relates to Zebra Minerals’ acquisition of the Penny West Gold Project

Venus Metals Corporation Limited (ASX:VMC) has reached an agreement to settle the proceedings against Spectrum MD Paul Adams, David Bosio and DJ Carmichael Pty Ltd in connection with the acquisition of the Penny West Gold Project.

The matter was to be heard by the Supreme Court of WA in March and the parties were attending a court-supervised mediation conference in relation to the proceedings.

The terms of the settlement agreement include:

  • an order be made that the case be dismissed;
  • the payment of a sum of $150,000 by DJ Carmichael (on behalf of DJ Carmichael, Bosio and Adams) to Venus Metals as a contribution to Venus Metals' legal costs; and
  • the payment is not made as a settlement sum but is purely a commercial settlement.

$850,000 settlement signed last week

Last week, Venus agreed to settle all claims against Spectrum Metals Limited and Zebra Minerals Pty Ltd arising from Zebra Minerals’ acquisition of the Penny West Gold Project.

Venus, Spectrum and Zebra have entered into a confidential agreement, which includes Spectrum paying to Venus an amount of $850,000.

Quick facts: Venus Metals Corporation Ltd

Follow
ASX:VMC

Price: 0.175 AUD

Market Cap: $26.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma Presenting at the One2One Virtual Forum - 16th September 2021

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. The Company is developing novel antimicrobial drugs from its “in-house” XF platform and also from recently acquired Biotherapeutic products that...

3 days, 11 hours ago

2 min read